Amgen offers a packed pipeline and healthy dividend distributions.Can a biotechnology company pay a generous dividend in 2024? The answer is definitely yes, as Amgen (AMGN 1.77%) is evidently unafraid to reward its loyal shareholders with quarterly cash payments.Just as importantly, Amgen is a recent revenue grower with a diversified pipeline of current and proposed products. So, here's the skinny on how much investors might expect from Amgen's upcoming dividend distributions.How much does Amgen pay in divi ...

The latest trading session saw Amgen (AMGN) ending at $330.83, denoting a +1.77% adjustment from its last day's close. This move outpaced the S&P 500's daily gain of 0.55%. At the same time, the Dow added 0.62%, and the tech-heavy Nasdaq gained 0.63%.The the stock of world's largest biotech drugmaker has risen by 8.91% in the past month, leading the Medical sector's gain of 0.19% and the S&P 500's gain of 4.28%.Analysts and investors alike will be keeping a close eye on the performance of Amgen in its upcom ...

With technology-driven growth stocks propelling the S&P 500 to new heights, dividend stocks have often found themselves playing catch-up.Yet, even in this market environment, some dividend-paying companies have managed not only to keep pace, but also beat the index by a significant margin.Specifically, while the S&P 500 has registered returns of about 27% over the past year, the following three dividend stocks have delivered annual total returns exceeding 30%.More importantly, these three stocks maintain eq ...

This company's payouts look safe.If there is one thing income investors like more than regular dividend payouts, it's regular and growing dividend payouts. Not every corporation can offer that, of course. Some will eventually suspend their dividend programs or, at the very least, decrease their payouts.Fortunately, there are stocks on the market that look committed to returning capital to their shareholders by way of consistent dividend increases. That's what income seekers are after. Let's consider one exc ...

Amgen's market-beating ways are unlikely to evaporate any time soon.Few stocks consistently outperform the vaunted S&P 500 index due to its inherent advantages in diversification and stability. This benchmark index draws its strength from a broad portfolio of America's top companies, allowing it to weather individual sector downturns and capitalize on various market trends simultaneously.Individual stocks, in contrast, are subject to company-specific risks and industry cycles. Even well-managed companies ca ...

PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of pancreatic adenocarcinoma is expanding in the developed world, and adaptive lifestyle habits such as alcohol and obesity may play a critical role. A report from Future Market Insights projects that the global pancreatic cancer mark ...

Can Amgen be a market-beating stock?Amgen (AMGN 0.89%) is a top drugmaker whose shares have risen by more than 70% in five years, which is a bit shy of the S&P 500's 90% gain over that stretch. With some promising products in its pipeline, the future does looks encouraging. However, some investors might be concerned about the company's high debt load.Here's where the business might go from here, and whether it's worth investing in Amgen today.Amgen could have a top weight loss drug in its portfolioThe bigge ...

Biotech stocks operate under a core ethos. While there’s been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing is more valuable than one’s health. If you can’t enjoy the fruits of your labor, then your labor will be meaningless. That’s why healthcare as a sector performs so well.Of course, being tied to a permanently relevant narrative doesn’t guarantee any individual enterprise success. However, one thing is clear. If you’ ...

SDI Productions/E+ via Getty Images Amgen Inc. (NASDAQ:AMGN) is one of the largest biopharmaceutical companies in the world, and it has been rapidly increasing its share of the global oncology medications market in recent years. Investment thesis The day after the company released its first-quarter 2024 financial results in early May, its share price rose more than 15%. In my opinion, the growth of Amgen's investment attractiveness in recent weeks is directly related to the successful integration of Horizon ...

Amgen (AMGN) announced that the FDA has granted approval to its leukemia drug, Blincyto, for consolidation treatment, regardless of measurable residual disease (MRD) status.Blincyto, a first-in-class Bispecific T-cell Engager (BiTE) therapy, is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of MRD status. ALL is a fast-growing type of blood ca ...